If you think someone who makes it into medical school cannot have ADHD, guess again: A recent review claims otherwise.

Executives from Biomea Fusion (NASDAQ:BMEA) discussed the company’s lead diabetes program, icovamenib, and outlined near-term ...

The Department of Administration has confirmed that about $7 million of a $13.1 million emergency appropriation passed by the ...

PARAMARIBO, Suriname — Suriname’s former president, Chandrikapersad Santokhi , an ex-police commissioner who investigated the 1982 killings of more than a dozen political opponents that deeply scarred ...

Before smartphones, spreadsheets, or even written alphabets as we know them, the Inca appear to have managed information in a ...

Evidence linking occupational light exposure to structural and functional eye damage CHENGDU, SICHUAN, CHINA, March 30, ...

The ASWA revamped its bylaws in 2021, as it looks forward to celebrating its 50th anniversary during the annual convention ...

Seismic Pharma, a newly formed biopharmaceutical company, today announced its launch and initial financing led by Panacea Capital. The company has been formed to advance a portfolio of clinically ...

Data from 615 participants across initial six sites, forming the most comprehensive multimodal dataset ever created for a ...

Peptides are being widely marketed as a “holy grail” for workout recovery and physical performance. But do they work?

The company's Biomea that is the lead program, icovamenib, is the first in the category of menin inhibitors directed to the treatment of both type 1 and type 2 diabetes that holds the potential to ...